The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells.

Maria E Camacho-MollJoni MacdonaldL H J LooijengaMichael P RimmerRoland DonatJohn A MarwickC J ShuklaNeil CarragherAnne JørgensenRod Thomas Mitchell

Published in: BMC cancer (2019)

These results suggest that manipulation of Gankyrin expression may reduce the cisplatin dose required for the treatment of TGCC, with benefits in reducing dose-dependent side effects of chemotherapy. Further studies are required in order to assess the effects of modulating Gankyrin on GCNIS/TGCC using in vivo models.

Keyphrases

poor prognosis
papillary thyroid
signaling pathway
squamous cell
locally advanced
binding protein
combination therapy
long non coding rna